retatrutide clinical trials phase 3 eli lilly trial A new trial from Eli Lilly and Company suggests Retatrutide, an investigational triple hormone

When used as a medication, GLP-1 receptor agonists mimic this hormone to support weight loss in a safe and medically supervised way

The diet category's 20222026 reset is the clearest recent case study, and the structural lessons apply far beyond weight management.

Nicklas WJ, Youngster SK, Kindt MV, Heikkila RE

Collectively, current evidence indicates that GLP-1 receptor agonist therapy induces substantial total weight loss that includes predictable reductions in fat-free mass (Table 1)

GLP-1 medications improve insulin sensitivity and reduce hyperinsulinemia, shifting the hormonal environment away from growth-factorrich conditions that may favor lesion survival

In this post, Ill examine blood sugar mechanisms, insulin sensitivity, and the important role of GLP-1, now used in pharmaceuticals for weight loss